Outsourcing in Clinical Trials Europe 201421-22 May 2014, Brussels, Belgium
With the Pharma/ Biotech industry growing year on year and the degree of outsourcing within clinical trials growing significantly, there comes a host of new challenges for pharmaceutical and biotech companies and it has never been more important to ensure that vendors are used to their maximum ability and at minimal cost.
This event will bring together senior industry representatives to discuss the latest challenges within clinical outsourcing such as vendor sourcing, selection and contracting, as well as communication, oversight and management. Outsourcing in Clinical Trials Europe will present itself as a unique forum for discussion and idea-sharing on innovative strategies within outsourcing models in this ever-growing region.
What benefits can outsourcing your clinical trials bring to your business?
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
We are always happy to see photos taken at our events! If you have any you would like to submit, please email firstname.lastname@example.org The Arena Team
Analysing both pre and post partnerships to enhance your strategy and make it fit for purpose
Contract Research Organization, Clinovo tells us about their experience and takeaways from Outsourcing in Clinical Trials Southern California.
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within pharmaceutical, biotechnology, and virtual companies across Europe:CEOCMOCSOCFO
US-based biopharmaceutical firm AbbVie has started a global Phase III clinical trial of an investigational oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor 'veliparib (ABT-888)' in patients with previously untreated locally …
Sweden-based Aprea, a Karolinska Development portfolio company, has started dosing patients in the Phase I/II clinical trial of APR-246 in combination with chemotherapy to treat ovarian cancer.
US-based biopharmaceutical firm Lexicon Pharmaceuticals has reported positive, top-line results from a Phase II clinical trial of LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), for the treatm…
UK-based biotechnology firm Critical Pharmaceuticals has announced the start of the first Phase I clinical trial of a nano-enabled intranasal teriparatide product in healthy post-menopausal women for the treatment of osteoporosis.
Merck has reported interim results from the ongoing C-WORTHy study, a multi-arm Phase II clinical trial assessing the efficacy and safety of an all-oral, once-daily regimen combining MK-5172 and MK-8742 in patients with chronic HCV Genotype 1 infecti…